PHIO Phio Pharmaceuticals Corp.

RXi Pharmaceuticals Corp is principally engaged in developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs.

$0.70  -0.02 (-3.20%)
As of 06/30/2022 16:00:00 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  11/19/2018
Outstanding shares:  13,658,722
Average volume:  185,732
Market cap:   $9,906,671
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   0.00
PB ratio:   0.49
PS ratio:   0.00
Return on equity:   -64.38%
Net income %:   0.00%